ZLNA ZELLUNA ASA

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. 

The minutes from the meeting are enclosed and available at the company’s website.

For further information, please see or contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA

Email: 

Phone:

Namir Hassan, CEO, Zelluna ASA

Email: 

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: 

Phone:  



 

Attachments



EN
25/11/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna announces collaboration with Etcembly for AI-enabled TCR engin...

Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering Oslo, Norway, 09 March 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration with Etcembly Ltd, a biotechnology company applying advanced machine learning to T cell receptor (TCR) discovery and engineering. Highlights: AI-enabled collaboration to engineer KKLC1-targeting TCRs for Zelluna's TCR-NK platformBuilds on successful engineering of MAGE-A4 TCR underpinning ...

March 9, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling

Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling Oslo, Norge, 9. mars 2026 – Zelluna (OSE: ZLNA) er et banebrytende selskap innen utvikling av allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjorde i dag et samarbeid med Etcembly Ltd, et bioteknologiselskap som anvender kunstig intelligens (AI) og avansert maskinlæring for optimalisering og utvikling av T-cellereseptorer (TCR). Høydepunkter: AI-drevet samarbeid for utvikling av KKLC1-rettede TCR-er til Zellunas TCR-NK-plattformBygger på v...

March 9, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 Firs...

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Comp...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 f...

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA) utvikler allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjør i dag at Medicines and Healthcare products Regulatory Agency (MHRA) og Research Ethics Committee (REC) i Storbritannia har godkjent selskapets søkna...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved w...

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025. Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast . Operational Highlights Q4 2025 CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's ...

February 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch